Skip to main content
. 2019 Apr 9;9:249. doi: 10.3389/fonc.2019.00249

Figure 2.

Figure 2

A combination of MPT0G413 and bortezomib synergistically inhibited multiple myeloma cell viability. (A) RPMI-8226 and NCI-H929 cells were treated with the indicated concentrations of MPT0G413, bortezomib, or both agents for 48 h. The effects on cell viability were analyzed using a MTT assay (left panel). The combination index values for the combination of MPT0G413 and bortezomib were calculated using CompuSyn software (middle and right panels). (B) RPMI-8226 and NCI-H929 cells were treated with MPT0G413 (4 μM in RPMI-8226 cells and 10 μM in NCI-H929 cells), bortezomib (2.5 nM), or combination therapy for 48 h, followed by staining with propidium iodide and annexin V and analysis by flow cytometry. (C) Proportions of apoptotic cells in response to the drug treatments described in (B). Results are shown as mean ± SEM from three independent experiments. ***p < 0.001 compared with the control group. ###p < 0.001 compared with the relevant control group. (D) RPMI-8226 and NCI-H929 cells were treated with MPT0G413 (2.5 μM), bortezomib (2.5 nM), or combination therapy for 12 h. Whole cell lysates were immunoblotted with the indicated antibodies.